These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3983334)

  • 1. Desipramine in the treatment of attention deficit disorder in adolescents.
    Gastfriend DR; Biederman J; Jellinek MS
    Psychopharmacol Bull; 1985; 21(1):144-5. PubMed ID: 3983334
    [No Abstract]   [Full Text] [Related]  

  • 2. Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine.
    Linet LS
    J Clin Psychiatry; 1987 Nov; 48(11):456. PubMed ID: 3479424
    [No Abstract]   [Full Text] [Related]  

  • 3. Desipramine in the treatment of children with attention deficit disorder.
    Biederman J; Gastfriend DR; Jellinek MS
    J Clin Psychopharmacol; 1986 Dec; 6(6):359-63. PubMed ID: 3805329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience.
    Riddle MA; Hardin MT; Cho SC; Woolston JL; Leckman JF
    J Am Acad Child Adolesc Psychiatry; 1988 Nov; 27(6):811-4. PubMed ID: 3198572
    [No Abstract]   [Full Text] [Related]  

  • 5. Growth deficits and desipramine.
    Holt KG
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1167-8. PubMed ID: 1429424
    [No Abstract]   [Full Text] [Related]  

  • 6. Desipramine in the treatment of adolescents with attention deficit disorder.
    Gastfriend DR; Biederman J; Jellinek MS
    Am J Psychiatry; 1984 Jul; 141(7):906-8. PubMed ID: 6375400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication for children with attention disorders.
    Colson ER
    Pediatrics; 1997 Jun; 99(6):922-3. PubMed ID: 9190559
    [No Abstract]   [Full Text] [Related]  

  • 8. New drug trials in attention deficit disorder.
    Rapoport JL; Zametkin A; Donnelly M; Ismond D
    Psychopharmacol Bull; 1985; 21(2):232-6. PubMed ID: 3923528
    [No Abstract]   [Full Text] [Related]  

  • 9. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample.
    Waring ME; Lapane KL
    Pediatrics; 2008 Jul; 122(1):e1-6. PubMed ID: 18595954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic medication in children and the QT interval: case report and discussion.
    Alderton HR
    Can J Psychiatry; 1995 Aug; 40(6):325-9. PubMed ID: 7585402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder.
    Higgins ES
    J Fam Pract; 1999 Jan; 48(1):15-20. PubMed ID: 9934377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
    Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
    Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of children and adolescents with bipolar disorder.
    Kowatch RA; DelBello MP
    Psychiatr Clin North Am; 2005 Jun; 28(2):385-97. PubMed ID: 15826738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of desipramine in children and adolescents with attention deficit disorder.
    Biederman J; Gastfriend D; Jellinek MS; Goldblatt A
    J Pediatr; 1985 Jun; 106(6):1017-20. PubMed ID: 3998940
    [No Abstract]   [Full Text] [Related]  

  • 18. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
    Visser SN; Lesesne CA; Perou R
    Pediatrics; 2007 Feb; 119 Suppl 1():S99-106. PubMed ID: 17272592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desipramine and cutaneous reactions in pediatric outpatients.
    Biederman J; Gonzalez E; Bronstein B; De Monaco H; Wright V
    J Clin Psychiatry; 1988 May; 49(5):178-83. PubMed ID: 2966797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.